A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen… - Investigational New …, 2020 - Springer
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
R Wesolowski, N Sharma, L Reebel… - … in medical oncology, 2019 - journals.sagepub.com
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with …
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with …
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
WD Tap, AS Singh, SP Anthony, M Sterba… - Clinical Cancer …, 2022 - AACR
Purpose: To assess the response to pexidartinib treatment in six cohorts of adult patients
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor …
Pexidartinib: first approval
YN Lamb - Drugs, 2019 - Springer
Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …
Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).
WD Tap, H Gelderblom, S Stacchiotti, E Palmerini… - 2018 - ascopubs.org
11502 Background: TGCT is a rare neoplasm of the joint/tendon sheath associated with
colony-stimulating factor 1 (CSF-1) overexpression. No approved systemic therapy is …
colony-stimulating factor 1 (CSF-1) overexpression. No approved systemic therapy is …
Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
H Gelderblom, AJ Wagner, WD Tap, E Palmerini… - Cancer, 2021 - Wiley Online Library
Background The objective of this study was to report on the long‐term effects of pexidartinib
on tenosynovial giant cell tumor (TGCT). Methods This was a pooled analysis …
on tenosynovial giant cell tumor (TGCT). Methods This was a pooled analysis …
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
Background Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm,
overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved …
overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved …
ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT)
W Tap - Future Oncology, 2020 - Taylor & Francis
Pexidartinib is the first approved medication in the USA for people with tenosynovial giant
cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at …
cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at …
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor
H Gelderblom, M de Sande - Future Oncology, 2020 - Taylor & Francis
Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. Phase III
ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult …
ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult …
Pexidartinib long‐term hepatic safety profile in patients with tenosynovial giant cell tumors
JH Lewis, H Gelderblom, M Sande, S Stacchiotti… - The …, 2021 - academic.oup.com
Background Pexidartinib is approved in the US for tenosynovial giant cell tumors (TGCTs).
Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs …
Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs …